The role of IL-10 in Infected Mice Due to Visceral Leishmaniasis
Peran IL-10 pada Tikus yang Terinfeksi Karena Leishmaniasis Visceral
DOI:
https://doi.org/10.21070/ijhsm.v2i1.88Keywords:
IL-10, mice, visceral LeishmaniasisAbstract
act. In this study, 30 Balb mice were inoculated with Leishmania donovani amastigote which was taken from a farm for growing visceral leishmaniasis, and 20 healthy Balb mice were taken as a control group. The mice ages ranged between (4-11) months. The study was conducted at the Veterinary Research Center in Diyala province during the period from March 2024 to January 2025. The results showed that the mean age of mice infected with visceral Leishmaniasis was (4-7) months 11 (22.0%) compared to the controls 8 (16.0%), and the mean age (8-11) was 18 (36.0%) compared to the controls 31 (62.0%) with no significant differences (P= 0.99). The prevalence of Leishmania donovani infection in male mice was 20 (40.0%) compared to the controls 36 (72.0%), which was more than females 9 (18.0%) compared to the controls with no significant variations (p=0.57). The mean level of anti Leishmania donovani IgG mice antibodies was (2.49±2.67) compared to the controls (0.83±0.57) with a highly significant variation (P= 0.003), and the mean level of IL-10 was (22.09±8.12) with a highly significant difference (P≤0.0001). The mean level of anti-leishmania donovani mice IgG antibodies in males was (2.74±3.18) compared to the controls (0.75±0.26) and the mean level of anti-leishmania donovani mice IgG antibodies in females was (20.55±0.67) compared to the controls (1.10±1.13) with no significant differences (P=0.52). While the mean level of IL-10 in males was (22.79±8.97) compared to the controls (4.81±1.91) and mean level of IL-10 in females was (20.55±6.00) compared to the controls (10.12±11.57) with no significant differences (P=0.36). The mean level of anti-leishmania donovani antibodies in mice age (4-7) months was (1.99±0.83) compared to the controls (0.68±0.26) and the mean level of anti-leishmania donovani antibodies in mice age (8-11) months was (2.79±3.33) compared to the controls (0.70±0.19) with no significant differences (P=0.26). While the mean level of IL-10 in age (4-7) months was (21.97±8.30) compared to the controls (1.70±0.60) and mean level of IL-10 in age (8-11) months was (22.16±8.25) compared to the controls (7.33±2.03) with no significant differences (P=0.24). There were a direct correlations between Leishmania donovani mice IgG antibody levels and IL-10 levels with (r=. 337*,. 337*) respectively. The correlations were highly significant (P=0.05), while our findings also showed negative correlations between Leishmania donovani mice IgG antibody level and ages at (r=-.-.001) and sex at (r=-.042) with (P= .994) and (P=.775) respectively. A mutation happened in IL-10 genes at rs1800876 SNPs, and wild TT was altered to CC & TC respectively in comparison to the control group with visceral leishmanial mice infection.
Highlights:
- No age or sex impact – Infection prevalence showed no significant differences.
- Strong immune response – Higher IgG and IL-10 levels in infected mice.
- Genetic mutation detected – IL-10 gene mutation linked to infection.
Keywords: IL-10, mice, visceral Leishmaniasis
References
[2] F. S. Almeida, Sh. E. R. Vanderley, F. C. Comberlang, et al., “Leishmaniasis: Immune Cells Crosstalk in Macrophage Polarization,” Trop. Med. Infect. Dis., vol. 8, no. 5, p. 276, 2023, doi: 10.3390/tropicalmed8050276.
[3] A. Lafleur, S. Daffis, Ch. Mowbray, et al., “Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis,” Vaccines, vol. 12, no. 10, p. 1179, 2024, doi: 10.3390/vaccines12101179.
[4] R. Singh, M. Kashif, P. Srivastava, et al., “Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host,” Pathogens, vol. 12, no. 5, p. 706, 2023, doi: 10.3390/pathogens12050706.
[5] M. Samant, U. S. Pandey, et al., “Role of Cytokines in Experimental and Human Visceral Leishmaniasis,” Front. Cell. Infect. Microbiol., vol. 11, p. 624009, Feb. 2021, doi: 10.3389/fcimb.2021.624009.
[6] S. Maksoud and J. El Hokayem, “The Cytokine/Chemokine Response in Leishmania/HIV Infection and Co-infection,” Heliyon, vol. 9, p. e15055, 2023.
[7] H. W. Murray, A. D. Luster, H. Zheng, and X. Ma, “Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver,” Infect. Immun., vol. 85, no. 1, p. e00824-16, 2017, doi: 10.1128/IAI.00824-16.
[8] Y. Huang, X. Guo, and Y. Wu, et al., “Nanotechnology’s Frontier in Combatting Infectious and Inflammatory Diseases: Prevention and Treatment,” Signal Transduct. Target. Ther., vol. 9, p. 34, 2024, doi: 10.1038/s41392-024-01745-z.
[9] G. Volpedo, Th. Pacheco-Fernandez, E. A. Holcomb, et al., “Mechanisms of Immunopathogenesis in Cutaneous Leishmaniasis and Post Kala-azar Dermal Leishmaniasis (PKDL),” Front. Cell. Infect. Microbiol., vol. 11, p. 685296, Jun. 2021, doi: 10.3389/fcimb.2021.685296.
[10] B. O. Osero, R. T. Aruleb, F. Brombacher, and R. Hurdayal, “Unraveling the Unsolved Paradoxes of Cytokine Families in Host Resistance and Susceptibility to Leishmania Infection,” Cytokine X, vol. 2, no. 4, p. 100043, Dec. 2020, doi: 10.1016/j.cytox.2020.100043.
[11] V. Carlini, D. M. Noonan, M. D. Noonan, and E. Abdalalem et al., "The Multifaceted Nature of IL-10: Regulation, Role in Immunological Homeostasis and Its Relevance to Cancer, COVID-19 and Post-COVID Conditions," Frontiers in Immunology, vol. 14, sec. Cancer Immunity and Immunotherapy, Jun. 2023. doi: 10.3389/fimmu.2023.1161067.
[12] J. Veronika, V. Seblova, and J. Votypka, "Xenodiagnosis of Leishmania donovani in BALB/c Mice Using Phlebotomus orientalis: A New Laboratory Model," Parasites & Vectors, vol. 8, no. 1, p. 765, Dec. 2015. doi: 10.1186/s13071-015-0765-x.
[13] N. E. Rodríguez, I. D. Lima, Upasna, and G. Dixit et al., "Epidemiological and Experimental Evidence for Sex-Dependent Differences in the Outcome of Leishmania infantum Infection," American Journal of Tropical Medicine and Hygiene, vol. 98, no. 1, pp. 142–145, Nov. 2017. doi: 10.4269/ajtmh.17-0563.
[14] F. K. Hussein, "Estimation of Immunoglobulin A, Immunoglobulin G, and Immunoglobulin M Antibody Levels in Laboratory Mice BALB/c Infected With Entamoeba histolytica and Treatment With Aqueous Extracts of Cyperus rotundus and Thymus serpyllum," Polytechnic Journal, vol. 10, no. 1, pp. 126-129, 2020. ISSN: 2313-5727. Available: http://journals.epu.edu.iq/index.php/polytechnic.
[15] G. G. Lima, A. I. Portilho, and E. De Gaspari, "Adjuvants to Increase Immunogenicity of SARS-CoV-2 RBD and Support Maternal–Fetal Transference of Antibodies in Mice," Pathogens and Disease, vol. 80, no. 1, p. ftac038, Oct. 2022. doi: 10.1093/femspd/ftac038.
[16] P. Gupta, T. Sághy, and M. Bollmann et al., "Local Immune Activation and Age Impact on Humoral Immunity in Mice, With a Focus on IgG Sialylation," Vaccines, vol. 12, no. 5, p. 479, 2024. doi: 10.3390/vaccines12050479.
[17] E. Farlane, Th. Mokgethi, and P. M. Kaye et al., "IL-4 Mediated Resistance of BALB/c Mice to Visceral Leishmaniasis Is Independent of IL-4Rα Signaling via T Cells," Frontiers in Immunology, vol. 10, sec. Microbial Immunology, Aug. 2019. doi: 10.3389/fimmu.2019.01957.
[18] L. Firmino-Cruz, T. D. Ramos, and A. M. Fonseca-Martins, "Immunomodulating Role of IL-10-Producing B Cells in Leishmania amazonensis Infection," Cellular Immunology, vol. 334, pp. 20-30, Dec. 2018. doi: 10.1016/j.cellimm.2018.08.014.
[19] C. W. Koloski, G. Hurry, and A. Foley-Eby et al., "Male C57BL/6J Mice Have Higher Presence and Abundance of Borrelia burgdorferi in Their Ventral Skin Compared to Female Mice," Ticks and Tick-borne Diseases, vol. 15, no. 2, p. 102308, Mar. 2024. doi: 10.1016/j.ttbdis.2024.102308.
[20] M. Casado-Bedmar, M. Roy, and E. Viennois, "The Effect of Sex-Specific Differences on IL-10−/− Mouse Colitis Phenotype and Microbiota," International Journal of Molecular Sciences, vol. 24, no. 12, p. 10364, 2023. doi: 10.3390/ijms241210364.
[21] M. Devender, P. Prince Sebastian, and V. K. Maurya et al., "Immunogenicity and Protective Efficacy of Tuzin Protein as a Vaccine Candidate in Leishmania donovani-Infected BALB/c Mice," Frontiers in Immunology, vol. 14, p. 1294397, 2023. doi: 10.3389/fimmu.2023.1294397.
[22] H. W. Murray, Ch. M. Lu, and S. Mauze et al., "Interleukin-10 (IL-10) in Experimental Visceral Leishmaniasis and IL-10 Receptor Blockade as Immunotherapy," Infection and Immunity, vol. 70, no. 11, pp. 6284–6293, Nov. 2002. doi: 10.1128/IAI.70.11.6284-6293.2002.
[23] D. Tadesse, A. Abdissa, and M. Mekonnen et al., "Antibody and Cytokine Levels in Visceral Leishmaniasis Patients With Varied Parasitemia Before, During, and After Treatment in Patients Admitted to Arba Minch General Hospital, Southern Ethiopia," PLoS Neglected Tropical Diseases, vol. 15, no. 8, p. e0009632, Aug. 2021. doi: 10.1371/journal.pntd.0009632.
[24] A. I. Olías-Molero, I. Moreno, and M. J. Corral et al., "Infection of Dogs by Leishmania infantum Elicits a General Response of IgG Subclasses," Scientific Reports, vol. 10, p. 18826, 2020. doi: 10.1038/s41598-020-75569-6.
[25] M. Hajiloo, A. Ahmadi, and P. Lotfi et al., "Is the Polymorphism at Position -1082 of IL-10 Gene Associated With Visceral Leishmaniasis?" Iranian Journal of Public Health, vol. 43, no. 8, pp. 1107–1112, Aug. 2014.
[26] A. V. B. Vieira, M. R. de Menezes, and P. C. S. Farias et al., "Human Visceral Leishmaniasis and Polymorphisms in Interleukin-Coding Genes: A Systematic Review," Venomous Animals and Toxins Including Tropical Diseases, vol. 30, p. e20240018, 2024. doi: 10.1590/1678-9199-JVATITD-2024-0018.
[27] P. Lypaczewski, W. Zhang, and G. Matlashewski, "Evidence That a Naturally Occurring Single Nucleotide Polymorphism in the RagC Gene of Leishmania donovani Contributes to Reduced Virulence," PLoS Neglected Tropical Diseases, vol. 15, no. 2, p. e0009079, Feb. 2021. doi: 10.1371/journal.pntd.0009079.
